Diagnostic Makers Seek Clarification On Biomarker Validation Standards
This article was originally published in The Gray Sheet
Executive Summary
FDA should elucidate biomarker terminology in finalizing its guidance on pharmacogenomic data submissions, Genzyme says in comments to the agency
You may also be interested in...
FDA To Launch Pharmacogenomics Website, Issue Guidance In March
FDA will publish its final guidance on voluntary pharmacogenomic data submissions in March, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko told the Drug Information Association meeting in Lisbon, Portugal March 9
FDA To Launch Pharmacogenomics Website, Issue Guidance In March
FDA will publish its final guidance on voluntary pharmacogenomic data submissions in March, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko told the Drug Information Association meeting in Lisbon, Portugal March 9
Cancer Segment Likely First Market For Roche’s SynergysDx Program
Roche Diagnostics is anticipating that the drive to commercialize pharmacogenomic technology will create a need for coordinated drug and diagnostic premarket efforts, triggering increased demand for development partnerships between the two sectors